Bioventus Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $581.8M+1.5% YoYTTM through 27 Jun 2026
Net Income $54.5MTTM through 27 Jun 2026
Free Cash Flow $94.3MTTM through 27 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 68.7% |
| EBITDA Margin | 17.8% |
| Operating Margin | 9.5% |
| Net Margin | 9.4% |
Returns
16.3%ROE
4.4%ROA
12.2%ROIC
Balance Sheet Health
Debt / Equity1.29x
Current Ratio1.70x
Net Debt$242.7M
Cash & Equivalents$29.5M
Quality Metrics
Altman Z-Score2.13
Piotroski F-Score7 / 9
FCF Margin16.2%
Rule of 4020.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $568.1M
Diluted EPS$0.78TTMFY2025: $0.33
Dividend
No dividend
Capital Allocation
R&D Spend$11.6M
Capex Intensity0.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| United States | $502.1M | -0.9% | |
| International | $66M | -0.7% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.